SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-284303
Filing Date
2023-11-28
Accepted
2023-11-28 16:21:29
Documents
12
Period of Report
2023-11-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d614921d8k.htm   iXBRL 8-K 23656
  Complete submission text file 0001193125-23-284303.txt   148604

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nmra-20231127.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20231127_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20231127_pre.xml EX-101.PRE 11712
6 EXTRACTED XBRL INSTANCE DOCUMENT d614921d8k_htm.xml XML 3470
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 231446747
SIC: 2836 Biological Products, (No Diagnostic Substances)